PerkinElmer, Inc. / EUROIMMUN Medizinische Labordiagnostika AG
2017 · Acquisition/Merger · $1.3B · Complete
Announcement Sentiment
92
Strongly positive
PerkinElmer agreed to acquire EUROIMMUN, a German leader in autoimmune testing and emerging player in infectious disease/allergy diagnostics, for approximately $1.3B. EUROIMMUN was expected to generate ~$310M revenue in 2017 with five-year average revenue growth of 19%. The deal expanded PerkinElmer's diagnostics portfolio across reproductive health, autoimmune, infectious disease and allergy testing. Closed December 2017.
Did it work? Outcome assessment
Strategic verdict
Achieved Stated Rationale
Financial impact
Accretive
Pipeline outcome
Assets Advanced
Assessment window: 5yr post-close.
Key facts
AnnouncedJun 19, 2017
ClosedDec 19, 2017
Deal value$1.3B
Deal typeAcquisition/Merger
Therapeutic areaAutoimmune disease, infectious disease and allergy diagnostics
IndicationsAutoimmune disease, infectious disease and allergy diagnostics
Key assetsAutoimmune, infectious disease and allergy IVD instruments and assays